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Abstract 
We explore how Deep Learning (DL) can be utilized to predict prognosis of acute 
myeloid leukemia (AML). Out of TCGA (The Cancer Genome Atlas) database, 94 AML 
cases are used in this study. Input data include age, 10 common cytogenetic and 23 most 
common mutation results; output is the prognosis (diagnosis to death, DTD). In our DL 
network, autoencoders are stacked to form a hierarchical DL model from which raw data 
are compressed and organized and high-level features are extracted. The network is 
written in R language and is designed to predict prognosis of AML for a given case (DTD 
of more than or less than 730 days). The DL network achieves an excellent accuracy of 
83% in predicting prognosis. As a proof-of-concept study, our preliminary results 
demonstrate a practical application of DL in future practice of prognostic prediction using 
next-gen sequencing (NGS) data.  
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INTRODUCTION 
AML is a neoplasm of the bone marrow that is caused by mutations or cytogenetic 
(chromosomal) abnormalities in the myeloid stem cells leading to the formation of 
aberrant myeloblasts.1 The highly proliferative cancer cells impede the formation of 
normal blood cells; leading to death if patients are left untreated.  There are about 
19,000 estimated new cases and 10,000 estimated deaths from this disease in 2018.2,3 
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There is an urgent need to find better treatments for this type of leukemia as only a 
quarter of the patients diagnosed with AML survive more than 5 years. AML includes 
many subtypes that share a common clinical presentation despite different types of 
mutations and genetic events.  A variety of technologies targeting the gene, mRNA, 
microRNA and protein level have helped predicting the prognosis of AML patients. 
Interestingly, most AMLs only have only a few gene mutations, but prognosis of AML 
patients is quite varied. A possible explanation for this diversity is differences in protein 
signaling. The genetic aberrations and mutations of myeloid leukemic cells often cause a 
profound impact on the cellular protein networks. 
 
Previous studies on the association between prognosis of AML and a small number of 
cytogenetic abnormalities and mutations highlighted the clinical and biologic 
heterogeneity of AML.4-8 The cytogenetic abnormalities with prognostic relevance have 
led to the adoption of a risk stratification model: three cytogenetically defined risk groups 
with significant differences in overall survival.9 Although risk stratification for AML 
patients has been improved to a great extent recently, a substantial number of patients 
still lack clear correlation between any specific abnormalities and accurate prognostic 
prediction. More recently, mutational analysis of FLT3, NPM1, and CEBPA was shown 
to improve risk stratification for AML patients without karyotypic abnormalities.10 
Recent advances in molecular studies, especially NGS, have identified additional 
recurrent somatic mutations in patients with AML, including mutations in TET2,11-12 
IDH1 and IDH2,13-15, DNMT3A,7,16 and PHF6,17 among others. Retrospective studies 
indicate that a subset of these mutations may have prognostic significance in AML,7,16,18 
and these mutations may be the “missing” parameters in previous risk stratification 
models for patients with AML. Whether including these novel mutations in mutational 
profiling with a larger set of genes would improve prognostication of AML has not been 
investigated in clinical studies. Numerous mutations in AML have been found with 
recent application of NGS technique.  The TCGA study19 with 200 AML cases showed 
that the average number of mutations is 13 per case and there are 23 recurrent mutations.  
Such a large number of mutations in AML would certainly present a challenge in 
predicting prognosis for AML patients using multiple-variable statistical analysis. 
 
In this paper, we propose the use of DL methods based on unsupervised feature 
extraction to address the challenge described above. Most successful DL methods involve 
artificial neural networks, a family of models inspired by biological neural networks (i.e. 
the central nervous system, particularly the brain). In such an artificial neural network, 
artificial nodes (known as "neurons") are connected to form a network mimicking a 
biological neural network. Warren McCulloch and Walter Pitts created a computational 
model for neural networks based on an algorithm called threshold logic in 1943.20 Neural 
networks had not shown superior performance compared to other machine learning 
methods until the introduction of DL in 2006. DL is different from traditional machine 
learning in how representations are learned from the raw data. In fact, DL allows 
computational models that are composed of multiple processing layers based on neural 
networks to learn representations of data with multiple levels of abstraction.21 Every layer 
of a deep learning system produces a representation of the observed patterns based on the 
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data it receives as inputs from the previous layer, by optimizing a local unsupervised 
criterion.22 The key aspect of deep learning is that these representations are not designed 
by human engineers, but they are learned from data using a general purpose learning 
procedure. Deep learning has recently shown impressive results in discovering intricate 
structures in high-dimensional data and obtained remarkable performances for object 
detection in images,23,34 speech recognition,25  natural language understanding26 and 
translation.27 Relevant clinical-ready successes have been obtained in health care as well 
(e.g. identification of metastatic breast cancer on lymph node slides,28 aggregating 
features relevant to specific breast cancer subtypes,29 predicting drug therapeutic uses and 
indications30), initiating the way toward a potential new generation of intelligent tools 
based on DL for real-world medical care. 
 
We use stacked autoencoders which form a deep network capable of achieving 
unsupervised learning, a type of machine-learning algorithm which draws inferences 
from the input data and does not use labeled training examples.  In contrast to previous 
methods of conventional neural network where data must be strictly categorized to 
provide the appropriate label for supervised learning, the unlabeled data in DL can be 
used in unsupervised training phase.  The resulting features from all training sets are then 
used as the basis for constructing the classifier.  
 
In this study, we use data from the TCGA database19 which consist of 200 de novo AML 
cases and attempt to use DL which incorporates unsupervised feature training to find 
correlation between cytogenetics, age, mutation and prognosis. To the best of our 
knowledge, unsupervised feature learning methods has never been applied to predict 
AML prognosis in this manner.  
 
MATERIALS AND METHODS 
Materials: 
Data from 200 cases of de novo AML were retrieved from TCGA database (public 
domain).17 Demographic information shows: age 55±16.1, white 89%, black 8%, others 
3%; male 54%, female 46%; normal cytogenetics 47%. Molecular testing was performed 
on multiple platforms: Affymetrix U133 Plus 2, Illumina Infinium Human Methylation 
450 BeadChip, and Affymetrix SNP Array 6.0. All karyotypes were analyzed by 
conventional G-banding in at least 20 metaphases. Results were available for 
cytogenetics, 260 gene mutations, and survival duration (DTD) for each case.31 As 
previously reported, in this database a total of 23 genes were significantly mutated, and 
another 237 were mutated in two or more samples.31 Nearly all samples had at least 1 
nonsynonymous mutation. To use the most relevant data for analysis, only cases with the 
following 23 most common mutations (grouped according to categories) were extracted 
for our study:  
-Activated signaling (signal transduction): FLT3-ITD, KIT, KRAS, NRAS, and PTPN11 
-Myeloid transcription factors (differentiation): NPM1, CEBPA, and RUNX1 
-Epigenetic regulation: DNMT3A, TET2, IDH2, IDH1, EZH2, and HNRNPK 
-Tumor suppressors: TP53, WT1, and PHF6 
-Spliceosomes: U2AF1 
-Cohesins: SMC1A, SMC3, STAG2, and RAD21, 
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-Non-annotated: FAM5C (BRINP3) 
 
Furthermore, the following 10 common cytogenetic abnormalities were seen in the 
patient cohort: t(8;21), inv(16), t(15;17), t(9:11), t(9;22), trisomy 8, del (7), del (5), del 
(20), and complex chromosomal abnormalities. Subsequently only 94 cases with one or 
more of the 23 common mutations were selected and included in this study.  These 
include cases with or without cytogenetic abnormalities. DTD was chosen as the 
prognostic parameter. For the 94 AML cases in this study, the mean DTD was 730 days. 
In summary, the number of input parameters was 34 (10 cytogenetics, age, and 23 
mutations) and the number of outcome parameter (DTD) was one. 
 
Methods 
Our main analysis method was a DL neural network with stacked (multi-layered) auto-
encoder. Training was mostly based on unsupervised feature learning which has been 
used successfully for image and audio recognition.32,33 Our DL neural network was 
designed with the R language. R is a programming language  for statistical 
computing and graphics supported by the R Foundation for Statistical Computing.34 R 
was derived from the S language which was originally developed at Bell Laboratories by 
John Chambers and colleagues. R's popularity has increased substantially in recent years 
with advances in machine learning.35 The source code for the R software environment is 
written primarily in Java, C, FORTRAN, and also in R itself.  R is freely available under 
the GNU General Public License, and pre-compiled binary versions are provided for 
various operating systems including UNIX, Windows and MacOS. In this study, we used 
many DL functions obtained from various R packages which are available from the 
Comprehensive R Archive Network.36  
 
The stacked autoencoder neural network, illustrated in Fig. 1, incorporates two training 
phases: pre-training with unsupervised learning method, and fine-tuning which is similar 
to the supervised back-propagation in conventional neural network.37,38 During pre-
training phase, the output from one layer is subsequently used as the input for the next 
output layer. The output from each layer essentially represents an approximation of the 
input data constructed from a limited number of features learnt by the hidden units of the 
network. The stacked autoencoder is constructed by multiple layers in the neural network 
(i.e. input layer, hidden layers, and output layer). For simplicity, only 2 layers are 
illustrated in Fig. 1. The sigmoid function is used as activation function in hidden layers. 
In fine-tuning phase, the back-propagation method minimizes the error with an additional 
sparsity penalty.39 The features learned in the pre-training phase are subsequently used 
with a set of labeled data for specific status (positive or negative) to train a classifier. A 
classifier can be defined as a function that receives values of various features from 
training examples (cytogenetics, age, and mutations as independent variables) and 
provides an output which predicts the category that each training example belongs to 
(prognosis or DTD as dependent variable).40 For the fine-tuning phase, we used linear 
function for the classifier.  
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Fig 1. A Deep Learning Neural Network (Stacked Autoencoder Network) with 
Unsupervised Training in Pre-training Phase and Supervised Training in the Fine-tuning 
phase 
 
 
 
For the initial analysis, all 34 attributes (10 cytogenetics findings, age, and 23 mutations) 
were used to train the network to predict prognosis (good prognosis vs. poor prognosis, 
i.e. DTD is either more than or less than 730 days).  A tenfold cross-validation method 
was used to obtain comprehensive validation results due to the small number of samples 
(94 cases). In this validation, a small subset of data (10 out of 94 cases) was excluded 
each time for training; the resultant trained network would be used to predict the 
prognostic status for each case in the excluded subset (the remaining 84 cases). The 
process was repeated until all 94 cases in the data set had been validated. The overall 
accuracy of the neural network is the mean of those for all the validated subsets. 
Subsequent analyses, using trial and error with different number of input parameters, are 
expected to show the optimal input for the most accurate prediction. 
 
RESULTS 
The initial use of the full attribute set (10 common cytogenetic abnormalities, age, and 23 
common mutations) yielded 81% accuracy for predicting good prognosis of an AML case 
(day-to-death > 730 days). This accuracy corresponded to a sensitivity of 74% and a 
specificity of 86% in predicting good prognosis of an AML case. The initial analysis 
showed that the following 14 attributes rank highest in term of predicting power among 
the 34 attributes: age, 7 cytogenetic abnormalities [tri8, del5, del7, complex chromosomal 
abnormalities, t(8;21), inv(16), t(15;17)], and 6 mutations [FLT3, NPM1, TP53, DNMT3, 
KIT, CEBPA]. Using these top-ranked 14 attributes, the DL network subsequently 
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achieved a slightly better accuracy of 83%, with a sensitivity of 80% and a specificity of 
85%. The accuracy in predicting prognostic status with different attribute sets by DL 
network is summarized in Table 1. Number of attributes smaller or larger than 14 did not 
yield better accuracy (data not shown) indicating that 14 is the optimal number of 
attributes for this study. It appeared that fewer than 14 attributes contain insufficient data 
for prediction. Conversely, more than 14 attributes introduced background noise, 
compromising accuracy.  
 
 
Table 1. Accuracy in Predicting Prognostic Status with Different Attribute Sets by the 
Deep Learning Network 
 34 Attribute Set 14 Attribute Set 
Conventional  Validation Set 
No. 
Accuracy Validation Set 
No. 
Accuracy 
1 90% 1 90% 
2 80% 2 70% 
3 80% 3 80% 
4 90% 4 90% 
5 100% 5 90% 
6 80% 6 80% 
7 70% 7 70% 
8 70% 8 80% 
9 80% 9 100% 
10 75% 10 80% 
Mean= 81%* Mean= 83% ** 
Legends: 
*   corresponding to sensitivity of 74%, and specificity of 86% 
** corresponding to sensitivity of 80%, and specificity of 85% 
 
 
The use of machine learning algorithms frequently involves careful tuning of network 
configuration and learning parameters. This tuning often requires experience, and 
sometimes brute-force search.41 During network training, we have tried various 
configurations for the neural network to achieve optimal accuracy and noted that our DL 
network performed best with 3 hidden layers consisting of 20, 15, 10 nodes, respectively. 
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The optimal learning parameters for our neural network, obtained through trial and error, 
were as follow42: Learning rate: 1.0, Momentum: 1.0, batch size=10, sigmoid function for 
activation and output. 
 
We also noted that the 3 general types of attributes (cytogenetics, age, or mutations) are 
almost equally important in predicting prognosis as expected. By separately leaving out 
cytogenetics, age, or mutations in the analysis, the accuracy for prognosis prediction 
degraded significantly to 67%, 61%, and 74%, respectively. 
 
DISCUSSION  
DL algorithms are new and innovative tools of research in machine learning to extract 
complex data representations at high levels of abstraction. In fact, DL has been cited as 
one of the 10 breakthrough technologies in 2013 by MIT Technology Review.43 The most 
important contribution of DL algorithms is to develop a hierarchical architecture of data, 
where higher-level features are defined in terms of lower-level features. The hierarchical 
learning architecture of DL algorithms is motivated by the biological structure of the 
primary sensorial areas of the neocortex in the human brain, which automatically extracts 
abstract features from the underlying data.44-46 DL algorithms rely on large amounts of 
unsupervised data, and typically learn data representations in a greedy layer-wise 
fashion.47,48 Studies have shown that data representations obtained from stacking up 
nonlinear feature extractors (such as autoencoders used in our study) often yield better 
machine classification results.49-51 
 
DL applications have produced outstanding results in several areas, including speech 
recognition,52-56 computer vision,47,48,57 and natural language processing.58,59, 28 A recent 
challenge hosted by the International Symposium on Biomedical Imaging (ISBI) in 2016 
lead to a successful DL system for automated detection of metastatic cancer from whole 
slide images of sentinel lymph nodes.60 Data-intensive technologies as well as improved 
computational and data storage resources have contributed to Big Data science.61 
Technology-based companies such as Microsoft, Google, Yahoo, and Amazon have 
maintained databases that are measured in exabyte proportions or larger. Various private 
and public organizations have invested in Big Data Analytics to address their needs in 
business and research,62 making this an exciting area of data science research.  
 
In the present study, we used DL to predict prognosis of AML. Specifically, we rely on a 
set of attributes (cytogenetics, age, and mutations) to predict prognostic status in newly-
diagnosed AML patients.  We implemented a DL network consisting of autoencoders that 
are stacked to form hierarchical deep models from which high-level features are 
compressed, organized, and extracted, without labeled training data. We showed how DL, 
which incorporates unsupervised feature training, can be used to predict prognosis using 
cytogenetics, age, and mutations with excellent results (accuracy of 83%, sensitivity of 
80%, and specificity of 85%).   
 
The main limitation of our preliminary study was the relatively small size of cohorts (94 
cases out of 200 from TCGA database). Nevertheless, this study provided excellent 
preliminary results for future studies that may include many more cases, more 
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cytogenetics and mutation data, and other clinical data such as co-morbidity index. With 
more data, it is expected that the accuracy would be higher than that from this 
preliminary study. 
 
CONCLUSION 
DL method, a disruptive technology, is predicted to be an integrated part of future 
practice in molecular diagnosis and prognostic prediction using NGS data. Our 
preliminary study demonstrated a practical application in this area. The successful 
validation of this DL software is of tremendous value to personalized treatment of AML 
patients, i.e. stratifying treatment especially bone marrow/stem cell transplant for each 
patient based on predicted prognosis. The software’s database can be continually kept up-
to-date by adding new patients’ data (with more patients, with additional tests, etc.) to 
improve its predicting ability. Furthermore, input ranking techniques in neural net can 
detect critical parameters which impact prognosis, and this helps to identify sets of 
important data to predict prognosis (novel patterns). While the amount of data used here 
was relatively modest, this study provided a proof-of-concept for using DL network as a 
more accurate approach for modeling big data in cancer genomics.  
 
Acknowledgement: The data in this study were provided by TCGA database which is 
available in public domain for research purpose. 
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